Trial Profile
Autologous Stem Cell Transplant With Pomalidomide (CC-4047) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Open-Label Randomized Study by Tristate Consortium
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary) ; Clarithromycin; Dexamethasone; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- 29 Jun 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 29 Jun 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 21 Jan 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.